Literature DB >> 11502519

In vitro activities of fluoroquinolones against the spirochete Borrelia burgdorferi.

P Kraiczy1, J Weigand, T A Wichelhaus, P Heisig, H Backes, V Schäfer, G Acker, V Brade, K P Hunfeld.   

Abstract

Little is known to date about the in vitro activity of fluoroquinolones against Borrelia species. Our study aimed at determining the in vitro activities of 15 quinolones against nine isolates of the Borrelia burgdorferi sensu lato complex in addition to one Borrelia valaisiana and one Borrelia bissettii tick isolate. For the determination of MICs, a standardized colorimetric microdilution method was applied. Determination of minimal borreliacidal concentrations providing 100% killing of the final inoculum (MBCs) after 72 h and time-kill experiments were performed by conventional culture in Barbour-Stoenner-Kelly medium in combination with dark-field microscopy. The rank order of potency on a microgram-per-milliliter basis for the substances with in vitro activity against B. burgdorferi was gemifloxacin (MIC at which 90% of the isolates tested are inhibited [MIC(90)], 0.12 microg/ml) > sitafloxacin (MIC(90), 0.5 microg/ml), grepafloxacin (MIC(90), 0.5 microg/ml) > gatifloxacin (MIC(90), 1 microg/ml), sparfloxacin (MIC(90), 1 microg/ml), trovafloxacin (MIC(90), 1 microg/ml) > moxifloxacin (MIC(90), 2 microg/ml), ciprofloxacin (MIC(90), 2 microg/ml) > levofloxacin (MIC(90), 4 microg/ml) > ofloxacin (MIC(90), 8 microg/ml), norfloxacin (MIC(90), 8 microg/ml) > fleroxacin (MIC(90), >16 microg/ml), and pefloxacin (MIC(90), 32 microg/ml) > nalidixic acid (MIC(90), 256 microg/ml). After 72 h of exposure, gemifloxacin was borreliacidal (100% killing) against the isolates investigated at a median MBC of 4 microg/ml. In the other compounds tested, median MBCs were higher (> or =8 microg/ml). Results of electron microscopy and time-kill studies clearly support an in vitro activity of some fluoroquinolones against borreliae. Our study demonstrates for the first time the enhanced in vitro effectiveness of some of the recently introduced 4-quinolones against B. burgdorferi.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11502519      PMCID: PMC90682          DOI: 10.1128/AAC.45.9.2486-2494.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

1.  Purification of pneumococcal type II topoisomerases and inhibition by gemifloxacin and other quinolones.

Authors:  I Morrissey; J T George
Journal:  J Antimicrob Chemother       Date:  2000-04       Impact factor: 5.790

Review 2.  Review of the in vitro activity of gemifloxacin against gram-positive and gram-negative anaerobic pathogens.

Authors:  E J Goldstein
Journal:  J Antimicrob Chemother       Date:  2000-04       Impact factor: 5.790

3.  Comparison of two laboratory methods for the determination of serum resistance in Borrelia burgdorferi isolates.

Authors:  P Kraiczy; K P Hunfeld; S Breitner-Ruddock; R Würzner; G Acker; V Brade
Journal:  Immunobiology       Date:  2000-01       Impact factor: 3.144

4.  Colorimetric in vitro susceptibility testing of penicillins, cephalosporins, macrolides, streptogramins, tetracyclines, and aminoglycosides against Borrelia burgdorferi isolates.

Authors:  K P Hunfeld; P Kraiczy; T A Wichelhaus; V Schäfer; V Brade
Journal:  Int J Antimicrob Agents       Date:  2000-06       Impact factor: 5.283

5.  Comparative bacteriostatic and bactericidal activities of cefodizime against Borrelia burgdorferi sensu lato.

Authors:  R Murgia; F Marchetti; M Cinco
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

6.  Natural synthesis of a DNA-binding protein from the C-terminal domain of DNA gyrase A in Borrelia burgdorferi.

Authors:  S W Knight; D S Samuels
Journal:  EMBO J       Date:  1999-09-01       Impact factor: 11.598

7.  Roxithromycin in Lyme borreliosis: discrepant results of an in vitro and in vivo animal susceptibility study and a clinical trial in patients with erythema migrans.

Authors:  K Hansen; A Hovmark; A M Lebech; K Lebech; I Olsson; L Halkier-Sørensen; E Olsson; E Asbrink
Journal:  Acta Derm Venereol       Date:  1992-08       Impact factor: 4.437

8.  In vitro antimicrobial susceptibility testing of Borrelia burgdorferi: a microdilution MIC method and time-kill studies.

Authors:  L L Dever; J H Jorgensen; A G Barbour
Journal:  J Clin Microbiol       Date:  1992-10       Impact factor: 5.948

9.  Lyme disease assay which detects killed Borrelia burgdorferi.

Authors:  S M Callister; R F Schell; S D Lovrich
Journal:  J Clin Microbiol       Date:  1991-09       Impact factor: 5.948

Review 10.  Isolation techniques for spirochetes and their sensitivity to antibiotics in vitro and in vivo.

Authors:  R C Johnson
Journal:  Rev Infect Dis       Date:  1989 Sep-Oct
View more
  12 in total

1.  parC mutations in fluoroquinolone-resistant Borrelia burgdorferi.

Authors:  Kendal M Galbraith; Amanda C Ng; Betsy J Eggers; Craig R Kuchel; Christian H Eggers; D Scott Samuels
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

2.  Screening of NCI-DTP library to identify new drug candidates for Borrelia burgdorferi.

Authors:  Venkata Raveendra Pothineni; Dhananjay Wagh; Mustafeez Mujtaba Babar; Mohammed Inayathullah; R Edward Watts; Kwang-Min Kim; Mansi B Parekh; Abhijit Achyut Gurjarpadhye; David Solow-Cordero; Lobat Tayebi; Jayakumar Rajadas
Journal:  J Antibiot (Tokyo)       Date:  2016-11-09       Impact factor: 2.649

Review 3.  Evidence assessments and guideline recommendations in Lyme disease: the clinical management of known tick bites, erythema migrans rashes and persistent disease.

Authors:  Daniel J Cameron; Lorraine B Johnson; Elizabeth L Maloney
Journal:  Expert Rev Anti Infect Ther       Date:  2014-07-30       Impact factor: 5.091

4.  In vitro susceptibility testing of Borrelia burgdorferi sensu lato isolates cultured from patients with erythema migrans before and after antimicrobial chemotherapy.

Authors:  Klaus-Peter Hunfeld; Eva Ruzic-Sabljic; Douglas E Norris; Peter Kraiczy; Franc Strle
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

Review 5.  Antimicrobial susceptibility of Borrelia burgdorferi sensu lato: what we know, what we don't know, and what we need to know.

Authors:  Klaus-Peter Hunfeld; Volker Brade
Journal:  Wien Klin Wochenschr       Date:  2006-11       Impact factor: 1.704

6.  Borrelia burgdorferi, the Causative Agent of Lyme Disease, Forms Drug-Tolerant Persister Cells.

Authors:  Bijaya Sharma; Autumn V Brown; Nicole E Matluck; Linden T Hu; Kim Lewis
Journal:  Antimicrob Agents Chemother       Date:  2015-05-26       Impact factor: 5.191

7.  In vitro susceptibility of Borrelia spielmanii to antimicrobial agents commonly used for treatment of Lyme disease.

Authors:  Kristina Morgenstern; Georg Baljer; Douglas E Norris; Peter Kraiczy; Christa Hanssen-Hübner; Klaus-Peter Hunfeld
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

8.  Destruction of spirochete Borrelia burgdorferi round-body propagules (RBs) by the antibiotic tigecycline.

Authors:  Øystein Brorson; Sverre-Henning Brorson; John Scythes; James MacAllister; Andrew Wier; Lynn Margulis
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-20       Impact factor: 11.205

9.  Comparison of in vitro activities of ketolides, macrolides, and an azalide against the spirochete Borrelia burgdorferi.

Authors:  Klaus-Peter Hunfeld; Thomas A Wichelhaus; Rebecca Rödel; Georg Acker; Volker Brade; Peter Kraiczy
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

10.  Diagnostic challenges of early Lyme disease: lessons from a community case series.

Authors:  John Aucott; Candis Morrison; Beatriz Munoz; Peter C Rowe; Alison Schwarzwalder; Sheila K West
Journal:  BMC Infect Dis       Date:  2009-06-01       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.